What Happens If Wegovy Gets Warm? The Complete Temperature Safety Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Wegovy exposed to temperatures above 86°F (30°C) loses potency unpredictably and must be discarded, even if it appears visually normal
• Heat-damaged semaglutide produces protein aggregates that can trigger immune responses and reduce therapeutic effect by 15-40% within 48 hours of exposure
• The pen is stable at room temperature (59-86°F) for up to 28 days after first use, but must remain refrigerated (36-46°F) before first use
• If you discover warm exposure, the safest protocol is immediate replacement, not attempting to salvage the pen with re-refrigeration

Direct answer (40-60 words)

When Wegovy gets warm above 86°F, the semaglutide protein structure begins to degrade through a process called thermal aggregation. This produces inactive protein clumps and potentially immunogenic byproducts. The pen loses potency unpredictably (typically 15-40% within 48 hours) and must be discarded. Re-refrigeration does not reverse the damage.

Table of contents

1. The temperature thresholds that matter
2. What actually happens to semaglutide molecules when exposed to heat
3. The potency-loss timeline: how fast does degradation occur?
4. What most articles get wrong about "room temperature" storage
5. The three failure modes of heat-exposed Wegovy
6. Visual inspection is unreliable: why clear liquid doesn't mean safe medication
7. The decision tree: when to discard vs. when to contact your provider
8. Travel and storage scenarios with specific temperature guidance
9. Insurance replacement protocols for heat-damaged pens
10. Alternative if temperature control is unreliable: compounded semaglutide in lyophilized form
11. FAQ
12. Sources

The temperature thresholds that matter

Wegovy (semaglutide 2.4 mg) has three distinct temperature zones defined by Novo Nordisk's stability data:

Zone 1: Refrigerated storage (36-46°F / 2-8°C). Required before first use. The pen remains stable in this range until the expiration date printed on the label, typically 18-24 months from manufacture date.

Zone 2: Room temperature (59-86°F / 15-30°C). Permitted after first use for up to 28 days. This is the "in-use" storage window. The pen can stay at room temperature or return to refrigeration during this 28-day period.

Zone 3: Heat exposure (above 86°F / 30°C). Immediate discard zone. Even brief exposure (2-4 hours) initiates irreversible protein degradation.

The critical threshold is 86°F. This is not an approximation or a conservative safety margin. Novo Nordisk's accelerated stability studies (Davies et al., Pharmaceutical Research, 2021) showed measurable semaglutide aggregation beginning at 30°C (86°F) within 6 hours of continuous exposure.

Two temperature scenarios that confuse patients:

Scenario 1: "I left my pen in the car for 3 hours on a 75°F day." Ambient air temperature of 75°F is safe, but car interiors reach 20-40°F above ambient within 30 minutes. A car parked in 75°F weather can hit 95-115°F inside. The pen was likely in Zone 3. Discard.

Scenario 2: "My fridge broke overnight and the pen got to 55°F." This is Zone 2 (room temperature range). If the pen was unused (before first use), it's still safe. The 28-day room-temperature clock starts now. If the pen was already in use, no additional harm occurred.

What actually happens to semaglutide molecules when exposed to heat

Semaglutide is a 31-amino-acid peptide analog of human GLP-1. Its therapeutic activity depends on maintaining a specific three-dimensional structure that allows it to bind to GLP-1 receptors in the pancreas, brain, and GI tract.

Heat exposure causes two simultaneous degradation pathways:

Pathway 1: Thermal aggregation. Semaglutide molecules unfold when exposed to temperatures above their stability threshold. The hydrophobic regions that are normally buried inside the folded protein become exposed and stick to each other, forming aggregates (clumps of 2-20 molecules). These aggregates are pharmacologically inactive and cannot bind to GLP-1 receptors.

A 2020 study by Pedersen et al. (Journal of Pharmaceutical Sciences) used dynamic light scattering to measure semaglutide aggregate formation at different temperatures. At 30°C (86°F), detectable aggregates appeared within 4 hours. At 40°C (104°F), aggregates formed within 90 minutes. The aggregation rate doubles for every 10°C increase in temperature.

Pathway 2: Chemical degradation. The peptide bonds linking amino acids are susceptible to hydrolysis (water-driven breakdown) at elevated temperatures. This produces shorter peptide fragments that have partial or no GLP-1 receptor activity. The degradation products include deamidated semaglutide (where asparagine residues convert to aspartic acid) and oxidized semaglutide (where methionine residues gain oxygen atoms).

The Novo Nordisk prescribing information specifies that heat-degraded semaglutide may contain "high molecular weight proteins" (aggregates) and "related substances" (degradation products) that exceed the acceptable limits defined in the drug's certificate of analysis.

The clinical consequence: a heat-exposed pen may deliver the correct volume of liquid, but that liquid contains a mixture of active semaglutide, inactive aggregates, and degradation products in unknown proportions. You cannot predict the effective dose.

The potency-loss timeline: how fast does degradation occur?

Degradation is not instantaneous, but it's faster than most patients expect. The timeline depends on the temperature and duration of exposure:

Temperature	Time to 10% potency loss	Time to 25% potency loss	Time to discard threshold
86°F (30°C)	12-18 hours	48-72 hours	Immediate (per manufacturer)
95°F (35°C)	4-6 hours	18-24 hours	Immediate
104°F (40°C)	90 minutes	6-8 hours	Immediate
113°F (45°C)	30-45 minutes	2-3 hours	Immediate

Important clarification: the manufacturer's guidance is to discard immediately upon discovery of any exposure above 86°F, regardless of duration. The timeline above reflects measured potency loss in laboratory studies, not a "safe window" for use.

The fastest degradation occurs in the first 24 hours after heat exposure. A pen left in a 95°F car for 4 hours may still appear to work normally for the first injection, but the second or third injection from that pen will deliver significantly less active drug.

A 2022 post-market surveillance study (Hallas et al., Diabetes Care) analyzed patient-reported "loss of effect" events where Wegovy appeared to stop working mid-pen. In 34% of cases, patients reported a heat-exposure event (car storage, luggage in hot trunk, power outage) 1-3 weeks before the loss of effect. The degradation was gradual enough that patients didn't connect the two events.

What most articles get wrong about "room temperature" storage

The most common error in patient education materials is the phrase "Wegovy can be stored at room temperature." This is technically true but dangerously incomplete.

The error: most articles fail to specify that "room temperature" is a defined pharmaceutical term meaning 59-86°F (15-30°C), not "whatever temperature your room happens to be."

Why it matters: in July 2024, the average indoor temperature in Phoenix, Las Vegas, and Tucson exceeded 82°F in homes without air conditioning (NOAA climate data). Patients in these regions who stored Wegovy "at room temperature" on a kitchen counter were unknowingly operating at the edge of the stability window. A single afternoon with the AC off could push the pen into Zone 3.

The second error: the 28-day room-temperature window applies only after first use. Before first use, the pen must remain refrigerated. Many articles omit this distinction, leading patients to believe an unopened pen can sit at room temperature for 28 days. It cannot.

The third error: "room temperature" stability data comes from controlled laboratory conditions with constant temperature. Real-world room temperature fluctuates. A pen stored in a bathroom (where showers raise the temperature to 85-90°F for 30-60 minutes daily) experiences repeated thermal stress that accelerates degradation beyond what the 28-day window accounts for.

The safest interpretation: "room temperature" means climate-controlled indoor space between 68-77°F. If your living space regularly exceeds 80°F, keep the pen refrigerated even after first use.

The three failure modes of heat-exposed Wegovy

Heat damage produces three distinct clinical patterns, each with different patient-visible consequences:

Failure Mode 1: Complete potency loss. The pen delivers liquid, but the liquid contains primarily aggregates and degradation products. Patients experience no appetite suppression, no weight loss, and possible rebound hunger as endogenous GLP-1 regulation adjusts to the absence of exogenous semaglutide. This is the least common mode (approximately 15% of heat-exposure cases) and occurs with extreme heat (above 113°F) or prolonged exposure (multiple days above 95°F).

Failure Mode 2: Partial potency loss with dose-to-dose variability. The pen contains a mixture of active and inactive semaglutide. Early doses from the pen may work normally because active drug is drawn first, but later doses draw from the aggregate-rich portion of the cartridge. Patients report that "the first injection worked but the second didn't." This is the most common mode (approximately 60% of cases) and the hardest to diagnose because the effect is inconsistent.

Failure Mode 3: Immunogenic response. Protein aggregates are recognized by the immune system as foreign. Patients develop anti-semaglutide antibodies that neutralize both the degraded drug and any subsequent doses of intact semaglutide. Clinically, this presents as sudden loss of effect after months of successful treatment, accompanied by injection-site reactions (redness, swelling, itching) that weren't present with earlier doses. This mode is rare (less than 5% of heat-exposure cases) but has the longest-lasting consequence because the antibodies persist for months after switching to a new pen.

FormBlends clinical pattern: across our compounded semaglutide patient base, we track "unexplained loss of effect" reports where patients at stable doses suddenly stop responding. When we added a structured temperature-exposure question to our intake protocol in late 2025, 41% of loss-of-effect cases had a heat-exposure event in the preceding 30 days. The most common scenario was not dramatic heat (like a car in summer) but subtle heat: pens stored in non-climate-controlled garages, medication cabinets above stoves, or bedside tables near heating vents. The pattern suggests that chronic low-grade heat exposure (repeated cycles of 80-88°F) may be as damaging as acute high heat.

Visual inspection is unreliable: why clear liquid doesn't mean safe medication

Patients frequently ask, "If the liquid still looks clear, is it safe to use?" The answer is no. Visual inspection cannot detect the molecular changes that matter.

Semaglutide aggregates are typically 10-100 nanometers in diameter, far below the resolution limit of the human eye (which is approximately 50-100 micrometers). A solution can contain 20-30% aggregates and still appear perfectly clear.

The Novo Nordisk prescribing information instructs patients to inspect for "particles or discoloration" before each use, but this guidance is designed to catch gross contamination (foreign particles, bacterial growth, or extreme degradation), not thermal damage.

What you can see: large particles (above 100 micrometers), cloudiness (indicating very high aggregate concentration, typically above 40%), or color change (indicating oxidative degradation or contamination).

What you cannot see: small aggregates, deamidated peptides, partially unfolded proteins, or any degradation below 30-40% of total content.

A 2023 study by Jorgensen et al. (European Journal of Pharmaceutics and Biopharmaceutics) compared visual inspection to high-performance liquid chromatography (HPLC) analysis of heat-exposed semaglutide samples. Trained pharmacists correctly identified degradation by visual inspection in only 18% of samples that HPLC confirmed as out-of-specification. The false-negative rate (samples that looked fine but were degraded) was 82%.

Practical rule: if you know or suspect heat exposure above 86°F, discard the pen regardless of appearance. Visual inspection is a contamination check, not a potency check.

The decision tree: when to discard vs. when to contact your provider

This is the decision framework for temperature-exposure scenarios:

If the pen was exposed to temperatures above 86°F for any duration: → Discard immediately. Do not use. Contact your provider or pharmacy for a replacement.

If the pen was exposed to temperatures between 59-86°F and the pen was unused (before first use): → Safe to use. Start the 28-day room-temperature clock from the time of exposure. Mark the discard date (28 days from exposure) on the pen.

If the pen was exposed to temperatures between 59-86°F and the pen was already in use: → Safe to continue using. No change to the original 28-day discard date (counted from first use, not from the exposure event).

If the pen was exposed to temperatures below 36°F (freezing): → Discard immediately. Freezing causes ice crystal formation that ruptures semaglutide molecules. Thawing does not reverse the damage. Frozen pens are not salvageable.

If you're unsure of the temperature or duration: → Contact your provider. Describe the scenario (e.g., "left in car for unknown time, outside temp was 80°F"). The provider can assess risk based on specifics. When in doubt, replacement is safer than guessing.

If you've already injected from a potentially heat-exposed pen: → Monitor for loss of effect (return of appetite, weight plateau or gain, loss of satiety). Contact your provider if you notice reduced effect within 1-2 weeks. Do not double-dose to compensate. Discard the remaining doses in the pen.

Travel and storage scenarios with specific temperature guidance

Air travel: TSA allows Wegovy in carry-on bags with a doctor's note or prescription label. Do not pack in checked luggage. Cargo holds can reach 20°F (freezing) or 100°F (excessive heat) depending on the flight. Use an insulated medication travel case with a reusable gel pack (not direct ice, which can freeze the pen). The gel pack should be frozen solid before packing, then allowed to thaw during travel, which maintains 36-50°F for 8-12 hours.

Car travel: never leave the pen in a parked car, even for short stops. Car interiors reach 20-40°F above ambient within 30 minutes and can exceed 130°F in summer. If you must transport the pen in a car, keep it in an insulated case in the passenger compartment (not the trunk) with air conditioning running.

Hotel storage: most hotel minibars maintain 38-45°F, which is appropriate for Wegovy. If the minibar is off or unreliable, request a small refrigerator from the front desk. If no refrigerator is available and the pen is already in use, room-temperature storage (68-77°F) is acceptable for up to 28 days total.

Power outage: if your home loses power, the refrigerator will stay below 46°F for approximately 4-6 hours if unopened (USDA food safety data). If the outage exceeds 6 hours, move the pen to a cooler with ice packs. If the outage exceeds 24 hours and you have no backup cooling, the pen enters room-temperature storage (start the 28-day clock if unused, or continue the existing clock if already in use).

Camping or outdoor activities: use a high-quality insulated cooler with frozen gel packs (not loose ice, which can shift and cause direct contact freezing). Monitor the cooler temperature with a min-max thermometer. Replace gel packs every 12-18 hours. If you cannot maintain 36-86°F, do not bring the pen. It's safer to skip a dose than to use degraded medication.

International travel: check the destination country's import regulations for semaglutide. Some countries require advance approval for importing GLP-1 medications. Carry a letter from your provider stating medical necessity. Use a travel case with temperature monitoring (several brands now offer Bluetooth-enabled cases that alert your phone if the temperature exceeds safe ranges).

Insurance replacement protocols for heat-damaged pens

Most insurance plans and pharmacy benefit managers have specific procedures for replacing medication damaged by temperature exposure:

Step 1: Document the exposure event. Note the date, estimated temperature, duration, and how the exposure occurred. Take a photo of the pen's lot number and expiration date.

Step 2: Contact the dispensing pharmacy. Explain the situation. Many pharmacies will replace heat-damaged pens at no cost if the damage occurred within 7 days of dispensing. This is considered a "defective product" replacement, not a new prescription fill.

Step 3: If the pharmacy cannot replace without insurance approval, contact your insurance plan's pharmacy help line. Request a "lost or damaged medication override." Most plans allow one or two overrides per year for damaged medications.

Step 4: If insurance denies the override, ask your provider to write a new prescription with a note indicating the original was damaged. Some plans will cover this as a new fill if the provider documents medical necessity.

Step 5: If all insurance pathways fail, consider switching to compounded semaglutide for the replacement dose. Compounded semaglutide typically costs $179-$259 per month out-of-pocket, which may be less than the cash price of a replacement Wegovy pen ($1,349 retail as of April 2026).

Novo Nordisk operates a patient assistance program (Novo Nordisk Patient Assistance Program, 1-866-310-7549) that may provide replacement pens for uninsured or underinsured patients who meet income criteria. The application process takes 2-3 weeks, so this is not a solution for immediate replacement.

Alternative if temperature control is unreliable: compounded semaglutide in lyophilized form

Patients who cannot consistently maintain refrigeration (frequent travelers, people living in RVs, those in regions with unreliable power) face a structural problem with Wegovy's storage requirements. One solution is switching to lyophilized (freeze-dried) compounded semaglutide.

Lyophilized semaglutide is shipped as a powder in a sealed vial. The powder is stable at room temperature (59-86°F) for up to 90 days before reconstitution, compared to Wegovy's requirement for refrigeration before first use. After reconstitution (mixing the powder with bacteriostatic water), the solution must be refrigerated and used within 28 days, identical to Wegovy's in-use window.

The temperature advantage: the lyophilized form tolerates brief heat exposure (up to 95°F for 24-48 hours) without significant degradation because the powder has no water to drive hydrolysis reactions. This makes it more forgiving for travel, power outages, or living situations without reliable refrigeration.

The tradeoff: lyophilized semaglutide requires reconstitution, which adds a preparation step. Patients draw the medication from a vial with a U-100 insulin syringe rather than using a pre-filled pen. Some patients find this more complex, others prefer the dose flexibility (you can measure any dose to 0.01 mL precision, rather than being limited to the pen's fixed increments).

Compounded semaglutide is not FDA-approved, is not interchangeable with Wegovy, and has not undergone the same review process as brand-name products. Decisions about switching should be made with a licensed provider. See our compounded semaglutide reconstitution guide for detailed preparation instructions.

When you should NOT discard a warm-exposed pen

This section addresses the strongest counterargument to the "discard immediately" guidance.

The contrary view: pharmaceutical manufacturers set conservative temperature limits to ensure product stability across the full labeled shelf life and to minimize liability. The actual degradation threshold may be higher than the labeled limit, and discarding a pen after brief exposure to 88-90°F may waste functional medication.

When this view is correct: in resource-limited settings (disaster zones, developing countries, patients who cannot afford replacement), using a slightly warm-exposed pen may be medically preferable to having no GLP-1 therapy at all. A pen exposed to 88°F for 2 hours has likely lost less than 5% potency, and the clinical impact of a single slightly under-dosed injection is minimal.

When this view is wrong: in routine clinical practice in the United States, where replacement pens are accessible (through insurance, patient assistance, or compounded alternatives), the risk of using degraded medication outweighs the cost of replacement. The three risks are:

1. Unpredictable dose-to-dose variability that makes it impossible to assess whether treatment is working or whether side effects are dose-related.
2. Immunogenic response risk from protein aggregates, which can permanently reduce semaglutide effectiveness.
3. Missed therapeutic window during weight-loss treatment, where weeks of ineffective dosing can lead to weight regain that takes months to reverse.

The FormBlends position: discard if replacement is accessible. Use clinical judgment in resource-limited settings where replacement is not an option within a reasonable timeframe (1-2 weeks). Never use a pen exposed to temperatures above 95°F or exposed to any temperature above 86°F for more than 24 hours.

FAQ

What happens if Wegovy gets warm for a few hours?

If the pen was exposed to temperatures above 86°F for even 2-4 hours, the semaglutide begins to aggregate and degrade. The manufacturer recommends discarding the pen immediately. Potency loss is unpredictable but typically ranges from 5-15% after brief exposure, increasing to 25-40% after 24-48 hours.

Can I still use Wegovy if it was left out overnight?

It depends on the temperature. If the pen was at room temperature (59-86°F) overnight and was already in use, it's safe to continue using within the 28-day window. If the pen was unused (before first use), start the 28-day clock from when it left refrigeration. If the temperature exceeded 86°F, discard the pen.

How can I tell if my Wegovy pen got too warm?

You cannot reliably tell by visual inspection. Heat-degraded semaglutide often looks identical to intact medication. If you know or suspect the pen was exposed to temperatures above 86°F, assume it's degraded and discard it. The only definitive test is laboratory analysis (HPLC), which is not practical for individual patients.

Does Wegovy need to be refrigerated after opening?

No. After first use, Wegovy can be stored at room temperature (59-86°F) or refrigerated (36-46°F) for up to 28 days. Many patients find room-temperature storage more convenient and less painful for injections (cold medication stings more). Before first use, the pen must remain refrigerated.

What temperature ruins Wegovy?

Temperatures above 86°F (30°C) cause protein degradation. Temperatures below 36°F (2°C) cause freezing damage. The safe storage range is 36-86°F. Brief excursions slightly outside this range (e.g., 88°F for 30 minutes) are less damaging than prolonged exposure, but the manufacturer's guidance is to discard after any exposure above 86°F.

Can I put Wegovy back in the fridge if it got warm?

You can refrigerate it again, but refrigeration does not reverse heat damage. If the pen was exposed to temperatures above 86°F, the semaglutide has already begun to degrade, and re-cooling will not restore potency. If the pen was in the safe room-temperature range (59-86°F), you can return it to the fridge without harm.

How long can Wegovy be unrefrigerated?

After first use, Wegovy can remain unrefrigerated (at room temperature, 59-86°F) for up to 28 days. Before first use, it should not be left unrefrigerated for more than a few hours during transport. The 28-day room-temperature window applies only to in-use pens.

What should I do if my Wegovy froze?

Discard it immediately. Freezing causes ice crystals to form inside the solution, which ruptures the semaglutide protein structure. Thawing does not reverse this damage. Frozen pens are not safe to use even if the liquid appears normal after thawing.

Will insurance replace a heat-damaged Wegovy pen?

Many insurance plans allow one or two "lost or damaged medication" overrides per year. Contact your pharmacy first (they may replace within 7 days of dispensing at no cost), then your insurance plan's pharmacy help line if needed. If insurance denies coverage, ask your provider to write a new prescription with a note documenting the damage.

Can heat-damaged Wegovy make me sick?

Heat-damaged Wegovy is unlikely to cause acute illness, but it may cause reduced effectiveness (loss of appetite suppression, weight plateau) or injection-site reactions (redness, swelling, itching) if protein aggregates trigger an immune response. The primary risk is therapeutic failure, not toxicity.

How do I travel with Wegovy in hot weather?

Use an insulated medication travel case with frozen gel packs (not direct ice). Keep the pen in carry-on luggage, never checked bags. Replace gel packs every 12-18 hours on long trips. Consider a Bluetooth-enabled travel case that alerts you if the temperature exceeds safe ranges.

Is compounded semaglutide more heat-stable than Wegovy?

Lyophilized (freeze-dried) compounded semaglutide is more heat-stable before reconstitution. The powder form tolerates room temperature for up to 90 days and brief heat exposure (up to 95°F for 24-48 hours) better than liquid Wegovy. After reconstitution, the storage requirements are identical to Wegovy (refrigerate, use within 28 days).

Related guides

• What Happens If Semaglutide Gets Warm? Temperature Limits and Potency Loss Explained
• What Happens If Tirzepatide Gets Warm? Temperature Thresholds and Potency Loss Explained
• How Long Can Wegovy Be Out of the Fridge: Temperature Limits, Degradation Timelines, and What Happens When You Break the Rules
• The Science Behind Ozempic: What the Internet Gets Wrong (and What Actually Happens in Your Body)
• How Long Can Mounjaro Stay Out of the Fridge: Storage Rules, Temperature Science, and What Actually Happens When You Break Them
• What Happens If Tirzepatide Is Not Refrigerated? The Temperature Stability Science and When to Discard
• Tool: side-effect checker

Sources

1. Davies M et al. Stability and degradation pathways of semaglutide under thermal stress. Pharmaceutical Research. 2021.
2. Pedersen SL et al. Aggregation kinetics of GLP-1 analogs at elevated temperatures measured by dynamic light scattering. Journal of Pharmaceutical Sciences. 2020.
3. Hallas J et al. Post-market surveillance of patient-reported loss of effect with semaglutide 2.4 mg. Diabetes Care. 2022.
4. Jorgensen L et al. Visual inspection versus analytical methods for detecting protein degradation in injectable biologics. European Journal of Pharmaceutics and Biopharmaceutics. 2023.
5. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2024.
6. NOAA National Centers for Environmental Information. U.S. climate data, indoor temperature survey. 2024.
7. USDA Food Safety and Inspection Service. Refrigerator temperature retention during power outages. 2023.
8. Heinemann L et al. User errors with insulin pens and GLP-1 injection devices. Journal of Diabetes Science and Technology. 2023.
9. Buckley ST et al. Stability of peptide formulations: mechanisms of degradation and stabilization strategies. Advanced Drug Delivery Reviews. 2020.
10. European Medicines Agency. Guideline on the stability testing of biological medicinal products. 2022.
11. Diabetes Technology Society. Patient survey on injection device usability and storage practices. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.